FINWIRES · TerminalLIVE
FINWIRES

Research Alert: CFRA Maintains Hold Opinion On Shares Of American Water Works Company, Inc.

By

-- CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:

We lower our 12-month target by $1 to $139, 21.2x our 2027 EPS estimate, a discount to AWK's five-year forward average of 25.1x. We keep our 2026 EPS view at $6.09 and lift 2027 EPS by $0.08 to $6.58. The Q1 EPS miss (-7.4%) is the latest in a series of misses, with seven in the last nine quarters coming in below expectations at an average of -3.1%. Our Hold opinion reflects our moderately balanced view of risks and rewards, particularly around the WTRG merger, though regulatory approval in Kentucky provides some relief to transaction uncertainty. We think higher for longer interest rates will pressure valuations. In the FOMC's most recent meeting, three regional presidents backed the hold on rates but rejected the statement's easing bias, which we interpret as a signal that the Fed's next move may not be a rate cut. We think the acceleration of closing expectations (June 30, 2026 vs. August 2026) for the Nexus Water Group Systems will boost 2026 sales, as we now anticipate 7% Y/Y growth.

Related Articles

Research

Research Alert: CFRA Maintains Hold Opinion On Shares Of Sonic Automotive Inc.

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We increase our 12-month price target by $15 to $85, based on a 2027 P/E of 10.8x, a premium to the stock's 10-year average forward P/E of 9.4x. We increase our adjusted EPS estimates to $7.05 from $7.00 for 2026 and to $7.85 from $7.60 for 2027. Following a much better-than-expected Q1 earnings release, we are raising our estimates and price target, but maintaing our Hold view on the shares. SAH posted Q1 adjusted EPS of $1.62 vs. $1.48 (+9%), well ahead of the $1.40 consensus. Revenue rose 1% to $3.69B ($40M below consensus) but gross margin expanded 70 bps to 16.2% (50 bps ahead of consensus). The quarter benefited from record adjusted EBITDA in the EchoPark segment (used vehicle sales). In our view, this was a solid release, highlighted by much better-than-expected margin performance and a notable increase in share repurchase activity, as SAH reduced its outstanding share count by a staggering 6% during Q1 (more than it bought back in all of 2025). We remain at Hold on valuation and a balanced risk/reward.

$SAH
Research

Research Alert: CFRA Maintains Buy Rating On Shares Of Tyler Technologies Inc.

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We lower our target price to $394 from $402, on a forward P/E of 31x our 2026 EPS projection of $12.71, below its three-year average but above peers on the resilience of the business. We increase our 2026 EPS projection to $12.71 from $12.57 and lift our 2027 EPS forecast to $14.28 from $14.19. TYL reported Q1 2026 revenue of $613.5M, up 8.6% Y/Y, led by exception SaaS revenue acceleration of 23.5% to $222.4M. Transaction-based revenues grew 6.4% to $207.4M. Customers are committing to cloud deployments as modernization efforts are underway and AI use skews toward greater cloud use. We expect this trend to sustain SaaS momentum, increasing our confidence in 20%-plus SaaS growth in the near to medium term. Non-GAAP operating margin expanded 40 bps to 27.2%, while adjusted EBITDA increased 9.3% to $177.3M, benefiting from favorable revenue mix toward higher-margin SaaS and transaction revenues, cloud efficiency gains, and disciplined expense management.

$TYL
Research

Research Alert: CFRA Maintains Buy Rating On Shares Of Labcorp Holdings Inc.

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We lower our 12-month price target to $300 from $325, 16.6x our 2026 EPS estimate, a premium to LH's three-year historical forward average of 15.3x, supported by our favorable view for health care services, including healthy lab testing volume growth within an environment of high medical utilization, as well as attractive growth prospects given new therapies and aging demographics, in our opinion. We raise our 2026 EPS estimate to $18.03 from $17.90 and raise our 2027 estimate to $19.32 from $19.15. Q1 2026 acquisitions were $202 million, including operations from Crouse Health's Laboratory Alliance of Central New York, while management expressed confidence in the upcoming deal pipeline during the Q1 earnings conference call. Acquisitions totaled $582 million during 2025. LH anticipates a 30 bps headwind for diagnostics volumes in 2026 due to the recent expiration of ACA enhanced premium tax credits, which we expect to cause a meaningful drop in ACA exchange insurance coverage.

$LH